5 results on '"Lee Jones, Scott"'
Number of results to display per page
Search Results
2. Testing Novel Strategies for Patients Hospitalized with HIV-associated Disseminated Tuberculosis (NewStrat-TB): Protocol for a Randomised Controlled Trial
- Author
-
Namale, Phiona E, primary, Boloko, Linda, additional, Vermeulen, Marcia, additional, Haigh, Kate A, additional, Bagula, Fortuna, additional, Maseko, Alexis, additional, Sossen, Bianca, additional, Lee-Jones, Scott, additional, Msomi, Yoliswa, additional, Mclleron, Helen, additional, Mnguni, Ayanda T, additional, Crede, Thomas, additional, Szymanski, Patryk, additional, Naude, Jonathan, additional, Ebrahim, Sakeena, additional, Vallie, Yakoob, additional, Moosa, Muhammed S, additional, Bandeker, Ismail, additional, Hoosain, Shakeel, additional, Nicol, Mark P, additional, Samodien, Nazlee, additional, Centner, Chad, additional, Dowling, Wentzel, additional, Denti, Paolo, additional, Gumedze, Freedom, additional, Little, Francesca, additional, Parker, Arifa, additional, Price, Brendon, additional, Schietekat, Denzil, additional, Simmons, Bryony, additional, Hill, Andrew, additional, Wilkinson, Robert, additional, Oliphant, Ida, additional, Hlungulu, Siphokazi, additional, Apolisi, Ivy, additional, Toleni, Monica, additional, Asare, Zimkhitha, additional, Mpalali, Mkanyiseli K, additional, Boshoff, Erica, additional, Prinsloo, Denise, additional, Lakay, Francisco, additional, Bekiswa, Abulele, additional, Jackson, Amanda, additional, Barnes, Ashleigh, additional, Johnson, Ryan, additional, Wasserman, Sean, additional, Maartens, Gary, additional, Barr, David, additional, Schutz, Charlotte, additional, and Meintjes, Graeme, additional
- Published
- 2024
- Full Text
- View/download PDF
3. Extended electrocardiographic monitoring in patients on chronic haemodialysis and after renal transplantation
- Author
-
Lee-Jones, Scott, Chin, Ashley, and Viljoen Charle
- Subjects
Medicine - Abstract
Background Chronic Kidney Disease (CKD) and chronic haemodialysis are associated with cardiovascular disease. Despite the increased risk of sudden cardiac death, few studies to date have described the burden of arrhythmias in this population. The aim of this study was to determine the prevalence, type and timing of arrhythmias by means of implantable loop recorder (ILR) monitoring in patients with CKD on chronic haemodialysis. Methods In this prospective cohort study, ILR's were implanted in twenty patients with CKD on the Renal Replacement Programme at Groote Schuur Hospital in Cape Town. Clinical, electrocardiographic and echocardiographic parameters were collected. We reviewed ILR recordings obtained between August 2015 and July 2018 and analysed arrhythmic events in relation to clinical parameters and temporal relation to dialysis sessions. Results In this cohort of 17/20 patients (1 died prior to ILR download and 2 lost to follow-up), the median age was 38 years (IQR 27.5 – 45) and left ventricular ejection fraction (LVEF) 62% (48 – 73). Clinically significant arrhythmias included atrioventricular (AV) block (n=24), atrial fibrillation (n=12) and non-sustained ventricular tachycardia (n=2). Most (57.4%) arrhythmic events occurred in the long interdialytic period between dialysis sessions. One patient with high degree AV block detected by ILR received a permanent pacemaker. Arrhythmic events were less prevalent after renal transplantation (6/17 during study period). Conclusion We have demonstrated that there is potential clinical utility of ILR monitoring in this population, which have a high risk of largely asymptomatic, clinically significant arrythmias. Larger studies are required to validate our findings.
- Published
- 2023
4. Risk Factors for Coronavirus Disease 2019 (COVID-19) Death in a Population Cohort Study from the Western Cape Province, South Africa
- Author
-
Boulle, Andrew, Davies, Mary-Ann, Hussey, Hannah, Ismail, Muzzammil, Morden, Erna, Vundle, Ziyanda, Zweigenthal, Virginia, Mahomed, Hassan, Paleker, Masudah, Pienaar, David, Tembo, Yamanya, Lawrence, Charlene, Isaacs, Washiefa, Mathema, Hlengani, Allen, Derick, Allie, Taryn, Bam, Jamy-Lee, Buddiga, Kasturi, Dane, Pierre, Heekes, Alexa, Matlapeng, Boitumelo, Mutemaringa, Themba, Muzarabani, Luckmore, Phelanyane, Florence, Pienaar, Rory, Rode, Catherine, Smith, Mariette, Tiffin, Nicki, Zinyakatira, Nesbert, Cragg, Carol, Marais, Frederick, Mudaly, Vanessa, Voget, Jacqueline, Davids, Jody, Roodt, Francois, van Zyl Smit, Nellis, Vermeulen, Alda, Adams, Kevin, Audley, Gordon, Bateman, Kathleen, Beckwith, Peter, Bernon, Marc, Blom, Dirk, Boloko, Linda, Botha, Jean, Boutall, Adam, Burmeister, Sean, Cairncross, Lydia, Calligaro, Gregory, Coccia, Cecilia, Corin, Chadwin, Daroowala, Remy, Dave, Joel A, De Bruyn, Elsa, De Villiers, Martin, Deetlefs, Mimi, Dlamini, Sipho, Du Toit, Thomas, Endres, Wilhelm, Europa, Tarin, Fieggan, Graham, Figaji, Anthony, Frankenfeld, Petro, Gatley, Elizabeth, Gina, Phindile, Govender, Evashan, Grobler, Rochelle, Gule, Manqoba Vusumuzi, Hanekom, Christoff, Held, Michael, Heynes, Alana, Hlatswayo, Sabelo, Hodkinson, Bridget, Holtzhausen, Jeanette, Hoosain, Shakeel, Jacobs, Ashely, Kahn, Miriam, Kahn, Thania, Khamajeet, Arvin, Khan, Joubin, Khan, Riaasat, Khwitshana, Alicia, Knight, Lauren, Kooverjee, Sharita, Krogscheepers, Rene, Kruger, Jean Jacque, Kuhn, Suzanne, Laubscher, Kim, Lazarus, John, Le Roux, Jacque, Lee Jones, Scott, Levin, Dion, Maartens, Gary, Majola, Thina, Manganyi, Rodgers, Marais, David, Marais, Suzaan, Maritz, Francois, Maughan, Deborah, Mazondwa, Simthandile, Mbanga, Luyanda, Mbatani, Nomonde, Mbena, Bulewa, Meintjes, Graeme, Mendelson, Marc, Möller, Ernst, Moore, Allison, Ndebele, Babalwa, Nortje, Marc, Ntusi, Ntobeko, Nyengane, Funeka, Ofoegbu, Chima, Papavarnavas, Nectarios, Peter, Jonny, Pickard, Henri, Pluke, Kent, Raubenheimer, Peter J, Robertson, Gordon, Rozmiarek, Julius, Sayed, A, Scriba, Matthias, Sekhukhune, Hennie, Singh, Prasun, Smith, Elsabe, Soldati, Vuyolwethu, Stek, Cari, van den berg, Robert, van der Merwe, Le Roux, Venter, Pieter, Vermooten, Barbra, Viljoen, Gerrit, Viranna, Santhuri, Vogel, Jonno, Vundla, Nokubonga, Wasserman, Sean, Zitha, Eddy, Lomas-Marais, Vanessa, Lombard, Annie, Stuve, Katrin, Viljoen, Werner, Basson, De Vries, Le Roux, Sue, Linden-Mars, Ethel, Victor, Lizanne, Wates, Mark, Zwanepoel, Elbe, Ebrahim, Nabilah, Lahri, Sa’ad, Mnguni, Ayanda, Crede, Thomas, de Man, Martin, Evans, Katya, Hendrikse, Clint, Naude, Jonathan, Parak, Moosa, Szymanski, Patrick, Van Koningsbruggen, Candice, Abrahams, Riezaah, Allwood, Brian, Botha, Christoffel, Botha, Matthys Henndrik, Broadhurst, Alistair, Claasen, Dirkie, Daniel, Che, Dawood, Riyaadh, du Preez, Marie, Du Toit, Nicolene, Erasmus, Kobie, Koegelenberg, Coenraad F N, Gabriel, Shiraaz, Hugo, Susan, Jardine, Thabiet, Johannes, Clint, Karamchand, Sumanth, Lalla, Usha, Langenegger, Eduard, Louw, Eize, Mashigo, Boitumelo, Mhlana, Nonte, Mnqwazi, Chizama, Moodley, Ashley, Moodley, Desiree, Moolla, Saadiq, Mowlana, Abdurasiet, Nortje, Andre, Olivier, Elzanne, Parker, Arifa, Paulsen, Chané, Prozesky, Hans, Rood, Jacques, Sabela, Tholakele, Schrueder, Neshaad, Sithole, Nokwanda, Sithole, Sthembiso, Taljaard, Jantjie J, Titus, Gideon, Van Der Merwe, Tian, van Schalkwyk, Marije, Vazi, Luthando, Viljoen, Abraham J, Yazied Chothia, Mogamat, Naidoo, Vanessa, Wallis, Lee Alan, Abbass, Mumtaz, Arendse, Juanita, Armien, Rizqa, Bailey, Rochelle, Bello, Muideen, Carelse, Rachel, Forgus, Sheron, Kalawe, Nosi, Kariem, Saadiq, Kotze, Mariska, Lucas, Jonathan, McClaughlin, Juanita, Murie, Kathleen, Najjaar, Leilah, Petersen, Liesel, Porter, James, Shaw, Melanie, Stapar, Dusica, Williams, Michelle, Aldum, Linda, Berkowitz, Natacha, Girran, Raakhee, Lee, Kevin, Naidoo, Lenny, Neumuller, Caroline, Anderson, Kim, Begg, Kerrin, Boerlage, Lisa, Cornell, Morna, de Waal, Renée, Dudley, Lilian, English, René, Euvrard, Jonathan, Groenewald, Pam, Jacob, Nisha, Jaspan, Heather, Kalk, Emma, Levitt, Naomi, Malaba, Thoko, Nyakato, Patience, Patten, Gabriela, Schneider, Helen, Shung King, Maylene, Tsondai, Priscilla, Van Duuren, James, van Schaik, Nienke, Blumberg, Lucille, Cohen, Cheryl, Govender, Nelesh, Jassat, Waasila, Kufa, Tendesayi, McCarthy, Kerrigan, Morris, Lynn, Hsiao, Nei-yuan, Marais, Ruan, Ambler, Jon, Ngwenya, Olina, Osei-Yeboah, Richard, Johnson, Leigh, Kassanjee, Reshma, and Tamuhla, Tsaone
- Subjects
sub-Saharan Africa ,0301 basic medicine ,Microbiology (medical) ,Adult ,Male ,Tuberculosis ,antiretroviral ,030106 microbiology ,Population ,HIV Infections ,HIV Infections/complications ,Cohort Studies ,South Africa ,03 medical and health sciences ,0302 clinical medicine ,Risk Factors ,Major Article ,Medicine ,Humans ,030212 general & internal medicine ,education ,Proportional Hazards Models ,education.field_of_study ,South Africa/epidemiology ,business.industry ,Proportional hazards model ,SARS-CoV-2 ,Hazard ratio ,HIV ,Correction ,COVID-19 ,medicine.disease ,Confidence interval ,AcademicSubjects/MED00290 ,Infectious Diseases ,Standardized mortality ratio ,tuberculosis ,Attributable risk ,business ,Viral load ,Demography - Abstract
Background Risk factors for coronavirus disease 2019 (COVID-19) death in sub-Saharan Africa and the effects of human immunodeficiency virus (HIV) and tuberculosis on COVID-19 outcomes are unknown. Methods We conducted a population cohort study using linked data from adults attending public-sector health facilities in the Western Cape, South Africa. We used Cox proportional hazards models, adjusted for age, sex, location, and comorbidities, to examine the associations between HIV, tuberculosis, and COVID-19 death from 1 March to 9 June 2020 among (1) public-sector “active patients” (≥1 visit in the 3 years before March 2020); (2) laboratory-diagnosed COVID-19 cases; and (3) hospitalized COVID-19 cases. We calculated the standardized mortality ratio (SMR) for COVID-19, comparing adults living with and without HIV using modeled population estimates. Results Among 3 460 932 patients (16% living with HIV), 22 308 were diagnosed with COVID-19, of whom 625 died. COVID-19 death was associated with male sex, increasing age, diabetes, hypertension, and chronic kidney disease. HIV was associated with COVID-19 mortality (adjusted hazard ratio [aHR], 2.14; 95% confidence interval [CI], 1.70–2.70), with similar risks across strata of viral loads and immunosuppression. Current and previous diagnoses of tuberculosis were associated with COVID-19 death (aHR, 2.70 [95% CI, 1.81–4.04] and 1.51 [95% CI, 1.18–1.93], respectively). The SMR for COVID-19 death associated with HIV was 2.39 (95% CI, 1.96–2.86); population attributable fraction 8.5% (95% CI, 6.1–11.1). Conclusions While our findings may overestimate HIV- and tuberculosis-associated COVID-19 mortality risks due to residual confounding, both living with HIV and having current tuberculosis were independently associated with increased COVID-19 mortality. The associations between age, sex, and other comorbidities and COVID-19 mortality were similar to those in other settings.
- Published
- 2021
- Full Text
- View/download PDF
5. Testing novel strategies for patients hospitalised with HIV-associated disseminated tuberculosis (NewStrat-TB): protocol for a randomised controlled trial
- Author
-
Namale, Phiona E., Boloko, Linda, Vermeulen, Marcia, Haigh, Kate A., Bagula, Fortuna, Maseko, Alexis, Sossen, Bianca, Lee-Jones, Scott, Msomi, Yoliswa, McIlleron, Helen, Mnguni, Ayanda Trevor, Crede, Thomas, Szymanski, Patryk, Naude, Jonathan, Ebrahim, Sakeena, Vallie, Yakoob, Moosa, Muhammed Shiraz, Bandeker, Ismail, Hoosain, Shakeel, Nicol, Mark P., Samodien, Nazlee, Centner, Chad, Dowling, Wentzel, Denti, Paolo, Gumedze, Freedom, Little, Francesca, Parker, Arifa, Price, Brendon, Schietekat, Denzil, Simmons, Bryony, Hill, Andrew, Wilkinson, Robert J., Oliphant, Ida, Hlungulu, Siphokazi, Apolisi, Ivy, Toleni, Monica, Asare, Zimkhitha, Mpalali, Mkanyiseli Kenneth, Boshoff, Erica, Prinsloo, Denise, Lakay, Francisco, Bekiswa, Abulele, Jackson, Amanda, Barnes, Ashleigh, Johnson, Ryan, Wasserman, Sean, Maartens, Gary, Barr, David, Schutz, Charlotte, Meintjes, Graeme, Namale, Phiona E., Boloko, Linda, Vermeulen, Marcia, Haigh, Kate A., Bagula, Fortuna, Maseko, Alexis, Sossen, Bianca, Lee-Jones, Scott, Msomi, Yoliswa, McIlleron, Helen, Mnguni, Ayanda Trevor, Crede, Thomas, Szymanski, Patryk, Naude, Jonathan, Ebrahim, Sakeena, Vallie, Yakoob, Moosa, Muhammed Shiraz, Bandeker, Ismail, Hoosain, Shakeel, Nicol, Mark P., Samodien, Nazlee, Centner, Chad, Dowling, Wentzel, Denti, Paolo, Gumedze, Freedom, Little, Francesca, Parker, Arifa, Price, Brendon, Schietekat, Denzil, Simmons, Bryony, Hill, Andrew, Wilkinson, Robert J., Oliphant, Ida, Hlungulu, Siphokazi, Apolisi, Ivy, Toleni, Monica, Asare, Zimkhitha, Mpalali, Mkanyiseli Kenneth, Boshoff, Erica, Prinsloo, Denise, Lakay, Francisco, Bekiswa, Abulele, Jackson, Amanda, Barnes, Ashleigh, Johnson, Ryan, Wasserman, Sean, Maartens, Gary, Barr, David, Schutz, Charlotte, and Meintjes, Graeme
- Abstract
Background: HIV-associated tuberculosis (TB) contributes disproportionately to global tuberculosis mortality. Patients hospitalised at the time of the diagnosis of HIV-associated disseminated TB are typically severely ill and have a high mortality risk despite initiation of tuberculosis treatment. The objective of the study is to assess the safety and efficacy of both intensified TB treatment (high dose rifampicin plus levofloxacin) and immunomodulation with corticosteroids as interventions to reduce early mortality in hospitalised patients with HIV-associated disseminated TB. Methods: This is a phase III randomised controlled superiority trial, evaluating two interventions in a 2 × 2 factorial design: (1) high dose rifampicin (35 mg/kg/day) plus levofloxacin added to standard TB treatment for the first 14 days versus standard tuberculosis treatment and (2) adjunctive corticosteroids (prednisone 1.5 mg/kg/day) versus identical placebo for the first 14 days of TB treatment. The study population is HIV-positive patients diagnosed with disseminated TB (defined as being positive by at least one of the following assays: urine Alere LAM, urine Xpert MTB/RIF Ultra or blood Xpert MTB/RIF Ultra) during a hospital admission. The primary endpoint is all-cause mortality at 12 weeks comparing, first, patients receiving intensified TB treatment to standard of care and, second, patients receiving corticosteroids to those receiving placebo. Analysis of the primary endpoint will be by intention to treat. Secondary endpoints include all-cause mortality at 2 and 24 weeks. Safety and tolerability endpoints include hepatoxicity evaluations and corticosteroid-related adverse events. Discussion: Disseminated TB is characterised by a high mycobacterial load and patients are often critically ill at presentation, with features of sepsis, which carries a high mortality risk. Interventions that reduce this high mycobacterial load or modulate associated immune activation could potentially reduc
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.